Us Congress House Bill HB1064

Us Congress 2025-2026 Regular Session

• Introduced: 2/6/25
• Refer: 2/6/25

Caption

Stopping Overdoses of Fentanyl Analogues ActThis bill permanently adds fentanyl-related substances to schedule I of the Controlled Substances Act. (A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.)Fentanyl-related substances are currently regulated under schedule I through a temporary order issued by the Drug Enforcement Administration. The temporary order expires March 31, 2025.

Impact

If enacted, HB1064 will impact federal drug enforcement policies by enabling stringent control over fentanyl analogs, thus facilitating law enforcement's ability to combat the rising epidemic of fentanyl overdoses and substance abuse. By treating fentanyl-related substances analogously to existing Schedule I drugs, the bill provides a legal mechanism to prosecute manufacturers and distributors of these substances more effectively. Furthermore, it represents a proactive approach to drug regulation, aiming to reduce the circulation of potentially dangerous synthetic opioids that have been linked to high rates of overdose fatalities across the country.

Summary

House Bill 1064, officially titled the 'Stopping Overdoses of Fentanyl Analogues Act,' seeks to amend the Controlled Substances Act by designating fentanyl-related substances as Schedule I controlled substances. This classification includes various modifications of fentanyl and aims to enhance the regulatory framework surrounding substances that are structurally related to fentanyl, which has become a significant concern in the ongoing opioid crisis. The bill proposes a comprehensive definition of fentanyl-related substances to ensure that a wider array of synthetic opioids can be controlled under federal law, thereby addressing the emergence of new analogues that pose risks to public health.

Contention

There are notable points of contention regarding the bill's implications for drug regulation and enforcement. Critics argue that while the intention behind HB1064 is to curtail the opioid crisis, it may inadvertently restrict access to legitimate medications that are critical for patients managing pain. Additionally, concerns have been raised about the potential for overreach in regulations, affecting researchers and manufacturers of pharmaceuticals containing controlled substances. Balancing the need for effective control against the possible negative effects on medical research and patient access remains a key debate as discussions around this legislation progress.

Congress_id

119-HR-1064

Policy_area

Crime and Law Enforcement

Introduced_date

2025-02-06